7 years ago

Metrion Biosciences Secures Funding to Expand Ion Channel Research

  • Metrion Biosciences, a UK-based specialist ion channel contract research and drug discovery company, has completed a funding round of undisclosed amount led by the o2h Ventures Therapeutics Fund, acting via Reyker Securities plc

  • The company will use the funds to broaden its ion channel screening capabilities and continue research into novel Kv1.3 inhibitors for the treatment of auto-immune conditions.

      • ProblemHealthcare

      "Developing new treatments for autoimmune diseases is challenging, and existing options often have significant side effects. Current treatments for autoimmune diseases often don't work well for all patients and can have serious side effects."

      Solution

      "Metrion Biosciences is focused on developing new drugs that target the Kv1.3 ion channel, which is implicated in autoimmune diseases. Their approach is to use cutting-edge technologies to discover and develop new drugs that are more effective and have fewer side effects."

      Covered on